Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + SRS for NSCLC Brain Metastases with Edema
NCT04147728Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Third Hospital. Primary endpoint: Edema Index at 1 month. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04147728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147728.